1. Home
  2. SLGL vs CVM Comparison

SLGL vs CVM Comparison

Compare SLGL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLGL
  • CVM
  • Stock Information
  • Founded
  • SLGL 1997
  • CVM 1983
  • Country
  • SLGL Israel
  • CVM United States
  • Employees
  • SLGL N/A
  • CVM N/A
  • Industry
  • SLGL Biotechnology: Pharmaceutical Preparations
  • CVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SLGL Health Care
  • CVM Health Care
  • Exchange
  • SLGL Nasdaq
  • CVM Nasdaq
  • Market Cap
  • SLGL 69.1M
  • CVM 63.3M
  • IPO Year
  • SLGL 2018
  • CVM 1987
  • Fundamental
  • Price
  • SLGL $39.30
  • CVM $9.89
  • Analyst Decision
  • SLGL
  • CVM
  • Analyst Count
  • SLGL 0
  • CVM 0
  • Target Price
  • SLGL N/A
  • CVM N/A
  • AVG Volume (30 Days)
  • SLGL 19.1K
  • CVM 125.1K
  • Earning Date
  • SLGL 11-14-2025
  • CVM 08-14-2025
  • Dividend Yield
  • SLGL N/A
  • CVM N/A
  • EPS Growth
  • SLGL N/A
  • CVM N/A
  • EPS
  • SLGL N/A
  • CVM N/A
  • Revenue
  • SLGL $23,931,000.00
  • CVM N/A
  • Revenue This Year
  • SLGL N/A
  • CVM N/A
  • Revenue Next Year
  • SLGL $31.17
  • CVM N/A
  • P/E Ratio
  • SLGL N/A
  • CVM N/A
  • Revenue Growth
  • SLGL 264.86
  • CVM N/A
  • 52 Week Low
  • SLGL $4.01
  • CVM $1.98
  • 52 Week High
  • SLGL $52.26
  • CVM $32.70
  • Technical
  • Relative Strength Index (RSI)
  • SLGL 67.60
  • CVM 52.53
  • Support Level
  • SLGL $34.80
  • CVM $8.69
  • Resistance Level
  • SLGL $52.26
  • CVM $10.62
  • Average True Range (ATR)
  • SLGL 4.38
  • CVM 0.66
  • MACD
  • SLGL 0.93
  • CVM 0.01
  • Stochastic Oscillator
  • SLGL 47.70
  • CVM 56.07

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Share on Social Networks: